American BioDefense Institute
The American BioDefense Institute is a Washington, D.C. based Think Tank, dedicated to nonpartisan analysis of U.S. and international biodefense capabilities and strategies, created in response to the COVID 19 pandemic. ABI challenges the conventional boundaries of scientific disciplines by combining expertise in medicine, biology, chemistry, communication, and public policy to provide multidirectional strategies to meet future biosecurity challenges. ABI Fellows represent some of the most accomplished academic and private sector pandemic and biodefense experts in the world. This highly specialized Institute advises the United States Congressional and Federal Agency community on next-generation tools, tactics, and procedures for effective biodefense and pandemic relief, as well as briefing federal stakeholders on the next generation of biological warfare threats. Contact Us: American BioDefense Institute Location: USA Email: abi@americanbiodefenseinstitute.org
American BioDefense Institute Launches ReOpen America, A Layered Bio-Hygiene Approach for Combating The Socio-Economic Impact of the COVID-19 Pandemic on the U.S. Arizona Congressman Paul Gosar Helps Kick Off the Effort During the Campaign’s Formal Launch In Prescott, Arizona Prescott, AZ., Sept. 21, 2020,/PRNewswire/ — American BioDefense Institute (A.B.I.) announced today the launch of its ReOpen America campaign, a bipartisan effort to reopen America’s economy, academia, and other elements of U.S. society.
The campaign kicked off in Arizona’s 4th Congressional District, a region led by biodefense maverick and U.S. congressman Paul Gosar, D.D.S. (R -AZ). Since the onset of the pandemic, A.B.I. has joined forces with several members of Congress, state governors, and other federal and local government officials to develop a much-needed strategy for addressing the “new normal” that was brought on by the Covid-19 pandemic. Their goal was to develop practical options for mitigating the pandemic’s adverse effect on American society and the economy as a whole. Fogging- A Powerful Disinfecting Layer for Biohygiene ? By: Nelly Nastase Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), most likely spreads through invisible respiratory droplets created when an infected person coughs or sneezes.
Those droplets can be inhaled by nearby people or land on surfaces that others might touch, spreading the infection when they touch their eyes, nose, or mouth (Science, 2020). There is a lot that is not fully known about the new SARS-CoV-2 virus, like how long does it remain active in the air or on surfaces. According to a recent study, the virus remains in the air for up to 3 hours and approximately 2-3 days on stainless steel and plastic surfaces (Van Doremalen et al, 2020). Another study found that a related SARS-CoV-1 virus that causes SARS can persist up to 9 days on non-porous surfaces such as plastic or stainless steel (Kampf et al, 2020). U.S. Rep. Paul Gosar talks about COVID-19.
Developing a New Model for Public Health During Pandemics - American BioDefense Institute’s. Join Us on August 13, 2020 1:00 PM – 2:00 PM EDT Learn about a new model for public health during pandemics, as well as Passive Immunity from expert thought leaders in biodefense, politics, sports, and media.
Register at theabiforum.org Join CBS News Homeland Security Correspondent Jeff Pegues, Congressman Paul Gosar, The New Orleans Saints all-time leading wide receiver Marques Colston, Executive Director of American BioDefense Institute Dr. Ravi Starzl, Attorney and Veteran advocate John Berry, and IP strategist JiNan Glasgow George for a one of a kind forum hosted by The American BioDefense Institute. Five months ago our health system was put to the test – and was found wanting. During the American BioDefense Institute forum, you’ll hear about a new model for public health that can interrupt the current pandemic, while ensuring our health system and society are better prepared for future threats.
Eli Lilly is testing a way to prevent covid-19 that’s not a vaccine. Nurses and patients in some US assisted living facilities will receive an antibody drug to prevent covid-19 infection, according to drug company Eli Lilly.
The drug: Early in the coronavirus pandemic, companies searched the blood of covid-19 survivors for potent antibodies against the novel virus. Eli Lilly’s drug is one of these Y shaped proteins—it’s a natural antibody manufactured at larger scale. The trial: To carry out the study, which will involve 2,400 people, Lilly will work with the National Institutes of Health to target nursing homes with covid-19 outbreaks. In some areas, elderly residents in nursing homes account for the majority of covid-19 deaths. How it works: Just like natural antibodies, Lilly’s antibody should grab onto the virus and block it. Passive immunity: Vaccines expose the body to a part of the pathogen, leading to “active immunity”—your body learns to makes its own antibodies against a germ.
Plan B: Antibody treatments could reach the market before a vaccine. American BioDefense Institute. Remote.com. About The American BioDefense Institute is a Washington, D.C. based Think Tank, dedicated to nonpartisan analysis of U.S. and international biodefense capabilities and strategies, created in response to the COVID 19 pandemic.
ABI challenges the conventional boundaries of scientific disciplines by combining expertise in medicine, biology, chemistry, communication, and public policy to provide multidirectional strategies to meet future biosecurity challenges. ABI Fellows represent some of the most accomplished academic and private sector pandemic and biodefense experts in the world. This highly specialized Institute advises the United States Congressional and Federal Agency community on next-generation tools, tactics, and procedures for effective biodefense and pandemic relief, as well as briefing federal stakeholders on the next generation of biological warfare threats. MooTools. Coub.com. Trello.